ArticleMedicine2026
Uncovering metabolite-inflammatory protein interactions in gout pathogenesis: A 2-sample bidirectional Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Gout is a widespread inflammatory arthritis whose current treatments focus mainly on symptom relief and urate lowering. Recent work suggests that circulating metabolites and inflammatory proteins interact in complex ways to influence disease risk, with fibroblast growth factor 19 (FGF19) standing out as a potential regulatory node linking metabolism and inflammation. We performed bidirectional 2-sample Mendelian randomization using genome-wide association study summary statistics for 1440 serum metabolites and 91 inflammatory proteins, with gout outcomes drawn from FinnGen R12. Mediation analyses were then applied to examine whether FGF19 acts as an intermediary in selected metabolite-gout pathways. Genetically predicted levels of vanillactate and histidine betaine were associated with higher gout risk, whereas sphingomyelin species and taurolithocholate 3-sulfate showed protective effects. Among inflammatory proteins, FGF19, adenosine deaminase and FGF5 appeared protective, while cluster of differentiation 244 increased risk. Bidirectional analyses revealed reciprocal relationships, including a negative causal effect of propionylcarnitine on FGF19. Mediation testing further showed that FGF19 explained 7.88% of the total effect of lipid-related metabolites on gout via glycodeoxycholate 3-sulfate and 9.58% via cis-3,4-methyleneheptanoylglycine. These findings indicate that FGF19 may exert protective effects against gout partly by modulating bile acid and fatty acid metabolism. The results offer genetic evidence for metabolic-immune crosstalk in gout pathogenesis and highlight FGF19-related pathways as possible targets for more precise therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.